These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 16549120

  • 1. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.
    Yakupoglu YK, Buell JF, Woodle S, Kahan BD.
    Transplant Proc; 2006 Mar; 38(2):358-61. PubMed ID: 16549120
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T, Kreis H, Friend P.
    Clin Transplant; 2004 Aug; 18(4):446-9. PubMed ID: 15233824
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen.
    Kahan BD, Podbielski J, Schoenberg L.
    Transplant Proc; 2006 Nov; 38(9):2842-6. PubMed ID: 17112844
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W, Schoenberg L, Lasky RE, Kahan BD.
    Transplant Proc; 2007 Dec; 39(10):3086-92. PubMed ID: 18089328
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Conversion to sirolimus in renal transplant patients with tumors.
    Sánchez-Fructuoso A, Conesa J, Perez Flores I, Ridao N, Calvo N, Prats D, Rodríguez A, Barrientos A.
    Transplant Proc; 2006 Oct; 38(8):2451-2. PubMed ID: 17097964
    [Abstract] [Full Text] [Related]

  • 11. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 12. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Conversion to sirolimus in pediatric renal transplantation recipients.
    Garcia CD, Bittencourt VB, Alves AB, Garcia VD, Tumelero A, Antonello JS, Malheiros D.
    Transplant Proc; 2006 Nov 15; 38(6):1901-3. PubMed ID: 16908317
    [Abstract] [Full Text] [Related]

  • 17. Higher incidence of acute rejection in renal transplant recipients with low everolimus exposure.
    Romagnoli J, Citterio F, Favi E, Salerno MP, Tondolo V, Spagnoletti G, Renna R, Castagneto M.
    Transplant Proc; 2007 Nov 15; 39(6):1823-6. PubMed ID: 17692622
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun 15; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.